Toronto Western Hospital
Welcome,         Profile    Billing    Logout  
 300 Trials 
480 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Laperriere, Normand
NCT04670016: HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

Recruiting
N/A
57
Canada
This study does not include an intervention.
University of Calgary, University of Toronto, Université de Montréal, University of Ottawa, Western University, Canada, McMaster University, Alberta Children's Hospital, Stollery Children's Hospital, British Columbia Children's Hospital, CancerCare Manitoba, Children's Hospital of Eastern Ontario, The Hospital for Sick Children, McMaster Children's Hospital, Children's Hospital Medical Center, Cincinnati, St. Justine's Hospital, Montreal Children's Hospital of the MUHC, IWK Health Centre, Janeway Children's Health and Rehabilitation Centre, Princess Margaret Hospital, Canada, London Health Sciences Centre, The Ottawa Hospital, CHU de Quebec-Universite Laval
DIPG, Brain Tumor, Pediatric, Recurrent, Brain Tumor, DIPG, Radiation Toxicity, Radiation Exposure, Brain Tumor, Pediatric
07/23
12/23
Kim, Edward S
COMMIT, NCT02997228: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the Study

Recruiting
3
120
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, Elplat, JM 83, JM-83, JM83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, RP54780, SR 96669, SR-96669, SR96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
06/27
06/27
NCT04379570: Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Recruiting
3
1180
US
Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Standard of Care, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8
10/26
10/26
NRG-LU008, NCT05624996: Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Recruiting
3
474
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Image Guided Radiation Therapy, IGRT, image-guided radiation therapy, Image-Guided Radiotherapy, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
NRG Oncology, National Cancer Institute (NCI)
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
10/31
10/36
OFSET, NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting
3
3960
Canada, US
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer
01/32
07/34
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
PARAMMUNE, NCT06203600: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Recruiting
2/3
224
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Questionnaire Administration, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC 1121B, IMC-1121B, IMC1121B, LY 3009806, LY-3009806, LY3009806, Monoclonal Antibody HGS-ETR2
National Cancer Institute (NCI)
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
10/27
10/27
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
EA2197, NCT04559139: Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

Recruiting
2/3
186
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Lymphadenectomy, excision of the lymph node, Lymph Node Dissection, lymph node excision, Partial Hepatectomy, partial excision of liver, subtotal hepatectomy
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
06/29
06/29
A222001, NCT04600336: Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

Completed
2
88
US
Oxybutynin Chloride, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Prostate Carcinoma
02/24
03/24
ETCTN 10476, NCT04941287: Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Active, not recruiting
2
56
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cobimetinib, Cotellic, GDC 0973, GDC-0973, GDC0973, MEK Inhibitor GDC-0973, XL 518, XL-518, XL518, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Varlilumab, CDX 1127, CDX-1127, CDX1127, Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer
National Cancer Institute (NCI)
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma
01/24
07/25
JANUS, NCT05610163: Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

Recruiting
2
312
US
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC V8, Stage III Rectal Cancer AJCC V8
09/25
09/32
NCT05724108: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Recruiting
2
94
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Lutetium Lu 177 Dotatate, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera, Lutetium (177Lu) Oxodotreotide, Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate, Lutetium Lu 177-DOTA-Tyr3-Octreotate, lutetium Lu 177-DOTATATE, Lutetium Oxodotreotide Lu-177, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Triapine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP, 3-Apct, OCX-0191, OCX-191, OCX191, PAN-811
National Cancer Institute (NCI)
Metastatic Neuroendocrine Tumor
03/25
03/25
VIRAGE, NCT05673811: Study of Nab-Paclitaxel and Gemcitabine and Plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

Active, not recruiting
2
96
Europe, US
Nab-paclitaxel, Gemcitabine, VCN-01
Theriva Biologics SL
Pancreatic Adenocarcinoma, Metastatic
04/25
04/25
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
NCT04597359: To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Recruiting
2
360
US, RoW
Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Sinecatechins, Camellia sinensis Leaf Catechins, Kunecatechins, Polyphenon E, Polyphenon E TM, Veregen
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Prostate Carcinoma
12/32
12/32
NCT03695250: BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Terminated
1/2
8
US
IDO1 Inhibitor BMS-986205, BMS 986205, BMS-986205, BMS986205, IDO-1 Inhibitor BMS-986205, Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205, ONO-7701, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Edward Kim, Bristol-Myers Squibb, National Cancer Institute (NCI)
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
11/20
03/21
NCT04068194: Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Recruiting
1/2
103
US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib
National Cancer Institute (NCI)
Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
12/25
12/25
ARYA-1, NCT04502082: Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma

Terminated
1/2
6
US
ET140203 autologous T cell product
Eureka Therapeutics Inc.
Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
06/23
06/23
ETCTN 10366, NCT04172532: Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Recruiting
1/2
98
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib, Placebo Administration
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
08/26
08/26
NCT04050085: SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Completed
1
6
US
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
University of California, Davis, National Cancer Institute (NCI), Bristol-Myers Squibb, Dynavax Technologies Corporation
Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/21
05/22
LIVELONG, NCT06101277: Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies

Recruiting
N/A
300
US
Ablative local therapy
University of California, Davis, National Cancer Institute (NCI)
Esophageal Cancer, Small Bowel Cancer, Gastroesophageal-junction Cancer, Gastric Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer, Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Oligoprogressive
12/25
01/31
NPC-QIC, NCT02852031: National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Recruiting
N/A
1000
Europe, Canada, US
Collaborative Learning Network
Children's Hospital Medical Center, Cincinnati
Hypoplastic Left Heart Syndrome (HLHS)
05/26
05/28
ASPEN, NCT05568472: Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, Study

Recruiting
N/A
540
US, RoW
Best Practice, standard of care, standard therapy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Endocrine Drug Therapy, Health Education, Questionnaire Administration, Symptom Specific Assessment Tool, Symptom Assessment Tool, Symptom-Specific Assessment Tool
SWOG Cancer Research Network, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
05/27
05/28
NRG-CC011, NCT05896189: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Recruiting
N/A
386
US
Arm 1: Computerized Cognitive Training-Global Stimulation Games, Arm 2: Computerized Cognitive Training-Neuroplasticity Games
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer, Cognitive Impairments
02/27
11/27
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
10000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30
Wong, Tien
DeepCHD, NCT06658600: Performance Evaluation of Artificial Intelligence Screening Model in Coronary Heart Disease Detection

Recruiting
N/A
900
RoW
Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease, Physician readers will be assisted with RF-CL table to calculate the probability of obstructive coronary heart disease
Tsinghua University, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Health and Medical Center
Coronary Heart Disease
01/25
01/25
Cheung, Angela M
NCT01896011: Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures

Completed
3
34
Canada
Teriparatide 20 mcg, Brand name Forteo, Placebo
University Health Network, Toronto, The Physicians' Services Incorporated Foundation, Eli Lilly and Company
Non Displaced Atypical Femoral Fractures
12/21
12/22
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites

Completed
3
410
Europe, Canada, US, RoW
Albutein 20% Injectable Solution, Standard medical treatment
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Decompensated Cirrhosis and Ascites
05/24
05/24
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
ESSOR, NCT05999435: Study of LAU-7b for the Treatment of Long COVID in Adults

Active, not recruiting
2/3
272
Canada
LAU-7b for 3 cycles, fenretinide, LAU-7b for 1 cycle, then placebo, Placebo for 3 cycles, sugar pill
Laurent Pharmaceuticals Inc.
Long COVID
08/24
10/24
RECLAIM - HBOT, NCT06452095: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition

Not yet recruiting
2/3
120
NA
Hyperbaric Oxygen therapy
University Health Network, Toronto
Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19
12/28
12/28
RECLAIM, NCT05513560: Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine

Suspended
2/3
460
Canada
Ibudilast, MN-166, Pentoxifylline, Placebo
University Health Network, Toronto
Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19
05/26
12/26
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Hi-OXSR, NCT06379620: Pilot Open Label Use of the for the Treatment of Post COVID-19 Cognitive Dysfunction

Completed
1
37
Canada
Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)
University Health Network, Toronto
Post COVID-19 Condition
03/24
03/24
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated
1
16
Europe, Canada, US, RoW
SAR439459, Placebo
Sanofi
Osteogenesis Imperfecta
11/24
11/24
NCT01155245: Teriparatide (PTH) and Bone Strength in Postmenopausal Women

Active, not recruiting
N/A
60
Canada
Forteo
University Health Network, Toronto, Eli Lilly and Company
Osteoporosis
01/24
01/25
NCT01747304: Evaluation of IVA (SE Femur Scans) to Identify Incomplete AFFs

Recruiting
N/A
500
Canada
DXA Se femur scans (previously called IVA femur), SF Femur scans
University Health Network, Toronto
Atypical Femur Fracture
12/24
12/25
NCT01155232: Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis

Recruiting
N/A
100
Canada
Teriparatide, Teriparatide is a section of the parathyroid hormone (PTH) given by injection., The drug is marketed by Eli Lilly under the name of Forteo
University Health Network, Toronto
Osteoporosis
01/25
01/26
NCT01747291: Atypical Fracture Cohort Study

Recruiting
N/A
300
Canada
University Health Network, Toronto
Atypical Femur Fracture, Atypical Subtrochanteric Fracture, Osteoporosis With AFf
12/25
12/26
NCT04110795: Personalizing Osteoporosis Care: Clinical & Genetic Risk Factors for AFFs

Active, not recruiting
N/A
1200
Canada
No Intervention
University Health Network, Toronto, Canadian Institutes of Health Research (CIHR)
Atypical Femur Fracture
12/25
12/27
NCT05541432: Finding the Optimal Resistance Training Intensity For Your Bones

Recruiting
N/A
324
Canada
Supervised strength training (group 1), Supervised strength training (group 2), Home exercise
University of Waterloo, Canadian Institutes of Health Research (CIHR), University of Saskatchewan, University Health Network, Toronto
Osteoporosis, Osteopenia
09/26
09/26
CaNAL, NCT03569826: Canadian Network for Autoimmune Liver Disease

Recruiting
N/A
2500
Canada
Observational; no intervention
University Health Network, Toronto
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
12/28
12/28
Shapiro, Colin M
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Completed
2
190
Canada, US
SUVN-G3031, Samelisant, Placebo
Suven Life Sciences Limited
Narcolepsy
06/23
06/23
NCT06247878: Skiin-PSG Sleep Apnea

Recruiting
N/A
200
Canada
Skiin underwear chest band
Myant Medical Corp., Jodha Tishon Inc
Obstructive Sleep Apnea
10/24
02/25
Hudson, Chris
NCT05903651: Retinal Deep PhenotypingTM

Completed
N/A
813
Canada
Optina Diagnostics Inc.
Healthy
03/24
03/24
Fehlings, Michael
MTRON, NCT02830451: Metastatic Tumor Research and Outcomes Network

Recruiting
N/A
960
Europe, Canada, Japan, US, RoW
AO Innovation Translation Center, AO Foundation, AO Spine
Metastatic Spine Tumor
12/25
12/25
NCT05653206: Incomplete Cervical SCI Without Instability

Recruiting
N/A
50
Europe, Canada, US, RoW
Nonsurgical treatment, Surgical treatment
AO Foundation, AO Spine
Cervical Spinal Cord Injury
05/26
08/27
NACTN, NCT00178724: Spinal Cord Injury Registry - North American Clinical Trials Network

Recruiting
N/A
1500
Canada, US
No Treatment Given
Robert G. Grossman, MD, Christopher Reeve Paralysis Foundation, The Methodist Hospital Research Institute, The University of Texas Health Science Center, Houston, University of Virginia, University of Louisville, University of Toronto, University of Maryland, Baltimore, Walter Reed National Military Medical Center, Thomas Jefferson University, University of Miami, Brooke Army Medical Center, Louisiana State University Health Sciences Center in New Orleans, Vanderbilt University Medical Center, Medical College of Wisconsin, Duke University
Spinal Cord Injury
07/25
07/28
Chan, Vincent
NCT04401007: Erector Spinae Plane (ESP) Block Volunteer Study

Active, not recruiting
N/A
24
Canada
Erector Spinae Plane Block with 1.5% lidocaine
University Health Network, Toronto
Pain Management
12/24
12/24
NCT03225508: Diaphragmatic Motion Using Linear Ultrasound

Completed
N/A
175
Canada
Linear Ultrasound to Measure Diaphragmatic Movement, Curvilinear Ultrasound to Measure Diaphragmatic Movement, Pulmonary function tests
University Health Network, Toronto
Diaphragm; Movement, Examination of Diaphragm Movement Using Ultrasound
05/24
05/24
NCT06680284: Toronto Western Hospital (TWH) Waste Audit

Recruiting
N/A
60
Canada
Staff Education Program
University Health Network, Toronto
Audit of Medical Waste Disposal
12/24
02/25
NCT03292497: Prospective Treatment Algorithm Guiding Repair of Severe Ischemic Mitral Regurgitation

Active, not recruiting
N/A
110
Canada
Treatment Algorithm, No Treatment Algorithm
Ottawa Heart Institute Research Corporation
Mitral Regurgitation
11/28
11/28
LAMBDA, NCT06547788: LEFT ATRIAL MONITORING IN PATIENTS BEFORE AND AFTER MITRAL SURGERY - STUDY

Not yet recruiting
N/A
50
Canada
Mitral valve repair with creation of an 8 mm inter-atrial shunt
Ottawa Heart Institute Research Corporation
Mitral Regurgitation, Mitral Valve Disease, Heart Failure
01/28
01/30
REVIVE, NCT04822675: REvascularization and Valve Intervention for Ischemic Valve diseasE: Trial

Recruiting
N/A
80
Canada
Percutaneous mitral valve repair, Surgical mitral valve repair/replacement
Ottawa Heart Institute Research Corporation
Mitral Valve Insufficiency, Coronary Artery Disease
08/25
08/26
NCT04198870: MitraClip REPAIR MR Study

Recruiting
N/A
500
Europe, Canada, US
MitraClip™ device implantation, Mitral Valve Repair Surgery
Abbott Medical Devices
Mitral Valve Regurgitation
04/26
04/34
NCT04811209: MCID and PASS for Acute Pain and Quality of Recovery After Orthopedic Surgery

Recruiting
N/A
300
Canada
1.Baseline Measurements Before Surgery, 2.Intraoperative Anesthetic Management, 3.Postoperative Analgesic Management, 4.Postoperative NRS Pain Assessment, 5.Postoperative Global Rating Scale (GRS) Pain Assessment, 6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain, 7.Postoperative Quality of Recovery Assessment, 8.Other Postoperative Assessments
University Health Network, Toronto
Pain Management
10/24
11/24
McIntyre, Roger
SMART-BD, NCT06433635: Sequential Multiple Assignment Randomized Trial for Bipolar Depression

Not yet recruiting
4
2726
Canada, US
Cariprazine, Vraylar, Aripiprazole/Escitalopram combination, Abilify/ Lexapro, Quetiapine, Seroquel, Lurasidone, Latuda
Massachusetts General Hospital, Patient-Centered Outcomes Research Institute
Bipolar I Disorder, Depression
02/30
02/30
NCT05047952: Vortioxetine for Post-COVID-19 Condition

Completed
2
149
Canada
Vortioxetine, Placebo
Brain and Cognition Discovery Foundation
Post-COVID-19 Condition, Post-COVID-19 Syndrome, Cognitive Impairment
02/23
02/23
NCT04209296: Chart Review of Patients Undergoing Ketamine Infusions

Completed
N/A
891
Canada
Ketamine Hydrochloride
Brain and Cognition Discovery Foundation
Major Depressive Disorder, Bipolar Disorder, Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder
09/23
09/23
Kennedy, Sidney H
CAN-BIND-17, NCT05017311: Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Recruiting
4
400
Canada
Escitalopram, Cipralex, Brexpiprazole, Rexulti
Nova Scotia Health Authority, Unity Health Toronto, Centre for Addiction and Mental Health, McMaster University, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Dalhousie University, University of Michigan, Simon Fraser University
Major Depressive Disorder
12/28
04/29
NCT04162522: Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

Completed
3
1
Canada
Escitalopram, Cipralex, Brexpiprazole, Rexulti
University Health Network, Toronto, Unity Health Toronto, Baycrest, Centre for Addiction and Mental Health, McMaster University, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Dalhousie University, University of Michigan, Simon Fraser University
Major Depressive Disorder
12/22
12/22
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT03674671: Ketamine Versus Electroconvulsive Therapy in Depression

Suspended
3
240
Canada
Intravenous Ketamine, Ketalar, Electroconvulsive Therapy, ECT
University of Ottawa, McGill University, Queen's University, University Health Network, Toronto, Ontario Shores Centre for Mental Health Sciences
Depressive Disorder, Major, Bipolar Depression
12/25
12/25
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression

Completed
2
197
Canada, US
Liafensine, Placebo
Denovo Biopharma LLC
Treatment Resistant Depression
02/24
03/24
NCT04495543: Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living'

Completed
N/A
77
Canada
Brief Skills for Safer Living, Brief-SfSL
Unity Health Toronto
Suicidal Ideation, Suicide, Mental Health Issue, Depression
03/23
03/23
ENABLE, NCT06408012: An Innovative Master Platform for Clinical Trials in Mood Disorders

Recruiting
N/A
900
Canada
St. Joseph's Healthcare Hamilton, Unity Health Toronto, Centre for Addiction and Mental Health, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Nova Scotia Health Authority, University of Michigan, Simon Fraser University, University Health Network, Toronto
Mood Disorders, Depressive Disorder, Bipolar and Related Disorders
03/26
03/26
Perlas, Anahi
NCT03225508: Diaphragmatic Motion Using Linear Ultrasound

Completed
N/A
175
Canada
Linear Ultrasound to Measure Diaphragmatic Movement, Curvilinear Ultrasound to Measure Diaphragmatic Movement, Pulmonary function tests
University Health Network, Toronto
Diaphragm; Movement, Examination of Diaphragm Movement Using Ultrasound
05/24
05/24
NCT06420739: The Semaglutide Study

Recruiting
N/A
100
Canada
Gastric Ultrasound
University Health Network, Toronto
Fasting
03/26
03/26
NCT06003985: Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

Recruiting
N/A
314
Canada, US
Gastric Ultrasound Exam
Hospital for Special Surgery, New York
Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
07/25
07/25
NCT04811209: MCID and PASS for Acute Pain and Quality of Recovery After Orthopedic Surgery

Recruiting
N/A
300
Canada
1.Baseline Measurements Before Surgery, 2.Intraoperative Anesthetic Management, 3.Postoperative Analgesic Management, 4.Postoperative NRS Pain Assessment, 5.Postoperative Global Rating Scale (GRS) Pain Assessment, 6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain, 7.Postoperative Quality of Recovery Assessment, 8.Other Postoperative Assessments
University Health Network, Toronto
Pain Management
10/24
11/24
Menard, Cynthia
PATRON, NCT04557501: PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

Active, not recruiting
3
800
Canada
PSMA PET/CT guided intensification of therapy, Control Arm
Centre hospitalier de l'Université de Montréal (CHUM), Canadian Cancer Society (CCS), Lantheus Medical Imaging, British Columbia Cancer Agency, London Health Sciences Centre, Princess Margaret Hospital, Canada, Tom Baker Cancer Centre, McMaster University, Institute of Health Economics, Canada, Queen's University
Prostate Cancer
01/29
01/29
fBTsRT, NCT04100174: Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

Recruiting
2
150
Canada
focal brachytherapy boost to SBRT
Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer
10/24
06/25
ANCHORProstate, NCT05457699: Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

Recruiting
2
80
Canada
SABR, no RT
Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer Metastatic
07/25
07/30
Lozano, Andres
NCT03650309: Deep Brain Stimulation for Morbid Obesity

Completed
N/A
6
Canada
Deep Brain Stimulation
University Health Network, Toronto
Obesity, Obesity, Morbid
01/22
07/22
NCT05175417: Visualization of Neural Targets With 3T MRI

Recruiting
N/A
40
Canada
MRI
University Health Network, Toronto
Neuro-Degenerative Disease
08/24
12/25
NCT02252380: ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

Active, not recruiting
N/A
10
Canada
Transcranial ExAblate System, MRgFUS, Focused Ultrasound, FUS
InSightec
Movement Disorders, Essential Tremor, Holmes Tremor, Parkinson's Disease, Wilson's Disease, Huntington's Disease, Dystonia, Tardive Dyskinesia, Orofacial Dyskinesias
06/23
12/23
NCT03153670: 3T MRI in Patients With Deep Brain Stimulation (DBS)

Recruiting
N/A
250
Canada
fMRI
University Health Network, Toronto
Neuro-Degenerative Disease
12/26
12/30
NCT04856072: Deep Brain Stimulation in Alzheimer's Disease: Biomarkers and Dose Optimization

Completed
N/A
11
Canada
Deep Brain Stimulation
University Health Network, Toronto, Johns Hopkins University
Alzheimer Disease
12/23
12/23
BRAINFUL, NCT04940507: (BRAIN Tumor Focused Ultrasound-enabled Liquid Biopsy) Trial

Recruiting
N/A
50
Canada
Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition, Neurosurgical Tumor Biopsy/Excision, Magnetic Resonance Guided Focused Ultrasound Thalamotomy
University Health Network, Toronto, Canadian Cancer Society (CCS), Brain Canada
Brain Neoplasms, Liquid Biopsy
06/24
06/26
BEST-FUS, NCT04501484: Bilateral Essential Tremor Treatment With FUS

Active, not recruiting
N/A
19
Canada
Magnetic Resonance-guided Focused Ultrasound VIM Thalamotomy
University Health Network, Toronto, Université de Sherbrooke
Essential Tremor
12/25
12/25
CAN-PRIME, NCT06700304: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

Recruiting
N/A
6
Canada
N1 Implant, R1 Robot
Neuralink Corp, University Health Network, Toronto
Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis (ALS), Spinal Cord Injury (Quadraplegia), Spinal Cord Injury
11/27
11/30
FRONSTIM, NCT05699330: Subgenual Cingulate Deep Brain STIMulation for Apathetic Behavioral Variant FRONtotemporal Dementia

Recruiting
N/A
6
Canada
Bilateral subgenual cingulate deep brain stimulation (SGC DBS)
University Health Network, Toronto, Weston Brain Institute
Frontotemporal Dementia, Deep Brain Stimulation
01/26
01/26
Fox, Susan H
MDC-CAN-PD, NCT03639064: Cannabis Oil for Pain in Parkinson's Disease

Recruiting
2
15
Canada
Cannabis Oil
University Health Network, Toronto, Parkinson Society Canada
Parkinson Disease
12/22
12/22
Bril, Vera
NCT06587867: Seronegative Myasthenia Gravis - Efgartigimod IV

Recruiting
3
30
Canada
efgartigimod
University Health Network, Toronto
Efgartigimod, Generalized Myasthenia Gravis
05/25
05/25
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Active, not recruiting
2
145
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
10/24
01/25
Wijeysundera, Duminda
RECOUP, NCT03675386: Reducing Opioid Use for Chronic Pain Patients Following Surgery

Recruiting
N/A
210
Canada
Interventional Group, Transitional Pain Service Program, Control Intervention
University Health Network, Toronto
Chronic Pain, Opioid Use, Postoperative Pain, Opioid Dependence
05/24
05/24
FAST Walk, NCT06412367: FUNCTIONAL ASSESSMENT FOR SURGERY BY A TIMED WALK

Recruiting
N/A
1672
Canada
Unity Health Toronto, Canadian Institutes of Health Research (CIHR), The Physicians' Services Incorporated Foundation
Surgery-Complications, Postoperative Complications
05/28
09/29
VALIANCE, NCT04973397: Vascular Events In Patients Undergoing Same-day Noncardiac Surgery () Study

Recruiting
N/A
15000
Europe, Canada, US
Centre hospitalier de l'Université de Montréal (CHUM), Canadian Institutes of Health Research (CIHR), Université de Montréal, Fonds de la Recherche en Santé du Québec
Preoperative Care, Surgery--Complications, Myocardial Infarction
08/25
08/26
Chan, Iris
NCT06413485: Canadian Beach Cohort Study

Active, not recruiting
N/A
5000
Canada
Level of recreational water contact activities, Sand contact at beaches
Toronto Metropolitan University, University of Waterloo, University of Guelph, Health Canada, Public Health Agency of Canada (PHAC), Toronto Public Health, Vancouver Coastal Health, Government of Manitoba, Public Health Niagara Region, McMaster University, Halifax Regional Municipality
Water-Related Diseases, Gastrointestinal Diseases
09/26
03/29
NCT04165408: Trial to Assess the Safety and Clinical Performance of Contino® in Preventing Urinary Incontinence

Recruiting
N/A
25
Canada
Contino
CMX Research
Urinary Incontinence
06/24
06/24
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Not yet recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
NCT04309695: The Zenflow Spring System Safety and Performance Study (ZEST CAN)

Recruiting
N/A
40
Canada
Zenflow Spring System
Zenflow, Inc.
Benign Prostatic Hyperplasia
12/25
01/26
Rajan, Dheeraj
AV PAS, NCT03506308: Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae

Recruiting
N/A
213
Canada, US
LUTONIX 035 Drug Coated Balloon PTA Catheter
C. R. Bard
Arteriovenous Fistula
09/25
03/30
WAVE, NCT04540302: The Merit WRAPSODY AV Access Efficacy Study

Active, not recruiting
N/A
357
Europe, Canada, US, RoW
Merit WRAPSODY Endovascular Stent Graft, PTA
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
02/24
01/26
WRAP, NCT05062291: Merit SODY™ Endoprosthesis for Treatment of Stenosis or Occlusion

Recruiting
N/A
500
Europe, RoW
Merit WRAPSODY Endovascular Stent Graft
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
12/25
07/27
Wong, Jean
INTACT-HIP, NCT05425355: Intravenous vs Oral Acetaminophen in Postoperative Hip Fracture Adult Patients

Not yet recruiting
4
42
NA
Intravenous (IV) acetaminophen + oral placebo, Intravenous (IV) placebo plus oral acetaminophen
University Health Network, Toronto
Hip-fracture, Surgery
03/24
06/24
NCT05594199: Feasibility of a Virtual Smoking Cessation Program

Recruiting
N/A
100
Canada
Virtual Smoking Cessation Program
University Health Network, Toronto
Smoking, Smoking Cessation, Smoking Reduction, Perioperative/Postoperative Complications, Fractures, Bone
04/24
09/24
FOCUS, NCT05094817: Feasibility of an Online, Self-administered Cognitive Screening Tool in Older Patients Undergoing Ambulatory Surgery

Completed
N/A
78
Canada
Brain Health Assessment, Demographics questionnaire, PHQ-2, AFT, GAI-SF, pain VAS, IADL, FAM CAM, 4AT, BHA Usability Survey, Clinical Frailty Scale
Women's College Hospital, University Health Network, Toronto
Delirium in Old Age, Alzheimer Disease, Mild Cognitive Impairment, Neurocognitive Disorders
07/23
07/23
 

Download Options